期刊文献+

经利妥昔单抗治疗后复发的皮肤B细胞淋巴瘤出现CD20信使RNA缺失

The absence of CD20 messenger RNA in recurrent cutaneous B- cell lymphoma following rituximab therapy
下载PDF
导出
出处 《世界核心医学期刊文摘(皮肤病学分册)》 2006年第2期19-19,共1页 Digest of the World Core Medical JOurnals:Dermatology
关键词 Background: RITUXIMAB has been used to TREAT relap Background: Rituximab has been used to treat relapsed low- grade or advanced non- Hodgkin' s lymphoma since 1997, targeting the CD20 antigen expressed by B cells. Single- agent rituximab therapy is safe and well tolerated. Recurrences showing a loss of CD20 expression following rituximab therapy have been reported. Methods: Four patients with CD20- positive cutaneous B- cell lymphoma received rituximab therapy with subsequent recurrences. The biopsies were assessed for cytoplasmic CD20 expression CD20 messenger RNA was also assessed where tissue was available. Results: Cutaneous relapses occurring within 1.5- 3 months following the last dose of rituximab were CD20 negative. In three cases, subsequent relapses showed renewed expression of CD20. Those biopsies demonstrating a loss of surface and cytoplasmic CD20 by immunohistochemistry also showed no evidence of messenger RNA for CD20 using an in situ polymerase chain reaction- based methodology. Conclusions: Rituximab may be associated with the emergence of CD20- negative B- cell clones, potentially rendering a tumor insensitive to this drug. Conversely, following cessation of the drug, a re- expression of CD20 within the neoplastic cells may occur allowing therapeutic intervention with this monoclonal antibody. The loss of CD20 expression appears to be a direct effect of the drug on CD20 messenger RNA synthesis.
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部